<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03304600</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01983-48</org_study_id>
    <nct_id>NCT03304600</nct_id>
  </id_info>
  <brief_title>tDCS for Treatment Resistant Obsessive Compulsive Disorder</brief_title>
  <acronym>tDCS-TOC</acronym>
  <official_title>Transcranial Direct Current Stimulation (tDCS) to Treat Patients With Severe and Resistant Obsessive Compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Henri Laborit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Henri Laborit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It's a multicentric, randomized, controlled study concerning 100 patients with
      treatment-resistant obsessive compulsive disorders (OCD). The aim of this study is to
      evaluate the effect of transcranial direct current stimulation (tDCS) on OCD patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale (YBOCS) score</measure>
    <time_frame>2 weeks</time_frame>
    <description>The primary objective of the study is to compare the change in Yale Brown Obsessive Compulsive Scale (YBOCS) scores from baseline to the week 2 (post-tDCS treatment) visit, between the two treatments groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale (YBOCS)</measure>
    <time_frame>Month 1</time_frame>
    <description>i. Change from baseline to month 1 in Yale Brown Obsessive Compulsive Scale (YBOCS) scores, between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale (YBOCS),</measure>
    <time_frame>Month 3</time_frame>
    <description>ii. Response rate at month 3 in Yale Brown Obsessive Compulsive Scale (YBOCS) score from baseline, between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>Month 1</time_frame>
    <description>Change from baseline to month 1 in above scales between treatment groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from baseline to month 3 in above scales between treatment groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brown Assessment of Beliefs Scale (BABS)</measure>
    <time_frame>Month 1</time_frame>
    <description>Change from baseline to month 1 in above scales between treatment groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brown Assessment of Beliefs Scale (BABS)</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from baseline to month 3 in above scales between treatment groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Anxiety Scale (BAS)</measure>
    <time_frame>Month 1</time_frame>
    <description>Change from baseline to month 1 in above scales between treatment groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Anxiety Scale (BAS)</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from baseline to month 3 in above scales between treatment groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery and Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Month 1</time_frame>
    <description>Change from baseline to month 1 in above scales between treatment groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery and Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from baseline to month 3 in above scales between treatment groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression scale (HAD)</measure>
    <time_frame>Month 1</time_frame>
    <description>Change from baseline to month 1 in above scales between treatment groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression scale (HAD)</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from baseline to month 3 in above scales between treatment groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale, (SDS)</measure>
    <time_frame>Month 1</time_frame>
    <description>Change from baseline to month 1 in above scales between treatment groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale, (SDS)</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from baseline to month 3 in above scales between treatment groups;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>3 Month</time_frame>
    <description>Safety of the tDCS treatment :
assessed by physical examination during each tDCS session
any other adverse events (AEs)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Active stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 sessions (1 per day during 2 week) of active tDCS stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>10 sessions (1 per day during 2 week) of sham stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active stimulation</intervention_name>
    <description>Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).</description>
    <arm_group_label>Active stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham stimulation</intervention_name>
    <description>Patients will receive a Sham stimulation during 30 mn</description>
    <arm_group_label>Sham Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria for obsessive compulsive disorder according to Diagnostic and
             Statistical Manual (DSM IV) with a &quot;good insight&quot; (BABS)

          -  No current depressive and suicidal risks

          -  No epileptic pathology

          -  Age: Participants will be both males and females, 18-70 years of age included.

          -  Chronic Obsessive compulsive disorder ( Total Y-BOCS&gt;20 or Y-BOCS one subscale &gt; 15)

          -  Obsessive compulsive disorder resistant to pharmacology treatment :

               1. at least 2 antidepressants (IRS type) (&gt; 12 weeks)

               2. cognitive and comportment therapy since at least one year

          -  Treatment stability (antidepressants) for more than 12 weeks without significant
             improvement.

          -  Affiliation to a social security system (recipient or assignee),

          -  Signed written inform consent form

        Exclusion Criteria:

          -  Female subject who is pregnant, or of child-bearing age, sexually active and not using
             reliable contraception or who is nursing,

          -  Patient under curators

          -  Patient hospitalized under duress

          -  Meets another diagnosis of axe 1 of DSM-IV

          -  Current depressive or suicidal risks

          -  Patient with any form of metal in the cranium, a pacemaker, skull defects, or skin
             lesions to the scalp (cuts, abrasions, rash)

          -  Epileptic patient

          -  Patient with a medical history of cranial trauma

          -  Patient unable to give his or hers informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damien HEIT, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Henri Laborit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damien HEIT, MD</last_name>
    <phone>+33 5 16 52 61 18</phone>
    <email>damien.heit@ch-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nematollah Jaafari, MD.PhD</last_name>
    <phone>+33 5 16 52 61 18</phone>
    <email>nemat.jaafari@ch-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils De Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rémy Bation, MD, PhD</last_name>
      <phone>04 72 11 80 64</phone>
      <email>remy.bation@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Rémy Bation</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marie VANELLE, Pr</last_name>
      <phone>+33 2.40.84.64.02</phone>
      <email>jeanmarie.vanelle@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Anne SAUVAGET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel BULTEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Henri Laborit</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien HEIT, MD</last_name>
      <phone>+33 5 16 52 61 18</phone>
      <email>damien.heit@ch-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Nematollah JAAFARI, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ghina HARIKA-GERMANEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.H. Guillaume Regnier</name>
      <address>
        <city>Rennes</city>
        <zip>35703</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique DRAPIER, Pr</last_name>
      <phone>+33 2 99 33 39 00</phone>
      <email>d.drapier@ch-guillaumeregnier.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique DRAPIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 29, 2017</study_first_submitted>
  <study_first_submitted_qc>October 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2017</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCD</keyword>
  <keyword>tDCS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

